Elixiron Immunotherapeutics - Taipei, Taiwan

Elixiron Immunotherapeutics is a pioneering global organization with a shared ambition to create the next generation of immunotherapies. We are focused on treating rare and inflammatory diseases, as well as cancer, with novel immunotherapy approaches that could have a valuable impact on patient care. Our research is driven by advances in translational medicine, allowing us to identify potential targets from clinical data and design various drug modalities, such as biologics from our proprietary human antibody domain phage display library and single human B cell antibody cloning platform. Our two primary pipeline candidates are currently in phase one clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being evaluated as a possible therapy for Alzheimer's  

Show more

disease and tenosynovial giant cell tumors, while EI-001, a monoclonal antibody, is being developed to treat vitiligo and other immunological disorders.